Cox regression analyses were further performed to determine the prognostic impact of RAS expressions in AML, and showed that KRAS was an independent prognostic biomarker in CN-AML (Table 2) but not in whole-cohort AML and non-APL AML patients (data not shown). This evidence concerns the gene KRAS and acute myeloid leukemia.